Who owns PRELUDE THERAPEUTICS INC?
- Ticker: PRLD
- CUSIP Number: 74065p101
Tip: Access positions for across all investors
Analyze quarterly positions in Prelude Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Prelude Therapeutics stock
Who bought or sold PRELUDE THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| OrbiMed Advisors | 11M | $47M | 0% | Dec 2023 |
|
| Baker Bros. Advisors | 10M | $43M | 0% | Dec 2023 |
|
| Deerfield Management Company | 4.1M | $18M | 100% | Dec 2023 |
|
| Boxer Capital | 2.6M | $11M | 3% | Dec 2023 |
|
| T. Rowe Price Associates | 1.0M | $4.5M | -2% | Dec 2023 |
|
| Vanguard Group | 1.0M | $4.3M | 3% | Dec 2023 |
|
| Massachusetts Financial Services | 511k | $2.2M | 0% | Dec 2023 |
|
| TD Asset Management | 161k | $686k | 0% | Dec 2023 |
|
| Jacobs Levy Equity Management | 131k | $561k | -9% | Dec 2023 |
|
| Charles Schwab Investment Management | 125k | $533k | 1% | Dec 2023 |
|
| Citadel Advisors | 97k | $414k | -68% | Dec 2023 |
|
| Millennium Management | 97k | $414k | 52% | Dec 2023 |
|
| Goldman Sachs Group | 70k | $297k | 3% | Dec 2023 |
|
| Exchange Traded Concepts | 64k | $303k | 45% | Mar 2024 |
|
| Two Sigma Advisers | 62k | $264k | 99% | Dec 2023 |
|
| Two Sigma Investments | 58k | $249k | 355% | Dec 2023 |
|
| Bank of New York Mellon | 40k | $190k | -21% | Mar 2024 |
|
| Bank of America Corporation | 38k | $160k | -29% | Dec 2023 |
|
| Jane Street | 33k | $141k | 100% | Dec 2023 |
|
| Barclays | 31k | $131k | 129% | Dec 2023 |
|
| Squarepoint Ops | 29k | $126k | -67% | Dec 2023 |
|
| State of Wisconsin Investment Board | 25k | $106k | -60% | Dec 2023 |
|
| Hsbc Holdings | 23k | $94k | 0% | Dec 2023 |
|
| Rhumbline Advisers | 20k | $87k | -40% | Dec 2023 |
|
| New York State Common Retirement Fund | 20k | $86k | 0% | Dec 2023 |
|
| UBS Group | 20k | $85k | 168% | Dec 2023 |
|
| Amundi | 15k | $61k | 100% | Dec 2023 |
|
| Dimensional Fund Advisors | 14k | $61k | 28% | Dec 2023 |
|
| Virtu Financial | 14k | $58k | 100% | Dec 2023 |
|
| SG Americas Securities | 13k | $56k | 100% | Dec 2023 |
|
| Jpmorgan Chase & Co | 9.4k | $40k | -46% | Dec 2023 |
|
| Royal Bank of Canada | 9.0k | $39k | 79% | Dec 2023 |
|
| American International | 7.4k | $32k | 4% | Dec 2023 |
|
| Wells Fargo & Company | 4.6k | $20k | 26% | Dec 2023 |
|
| Citigroup | 2.1k | $9.1k | 304% | Dec 2023 |
|
| Legal & General Group | 962.00 | $4.1k | 0% | Dec 2023 |
|
| Summit Investment Advisors | 819.00 | $3.5k | 0% | Dec 2023 |
|
| Amalgamated Bank | 334.00 | $2.0k | -61% | Mar 2024 |
|
| HighMark Wealth Management | 50.00 | $214.000000 | 0% | Dec 2023 |
|
| CWM | 2.00 | $0 | 100% | Mar 2024 |
|
Who sold out of Prelude Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| EcoR1 Capital | Sep 2023 | 1.2M | $3.6M |
| GSA Capital Partners | Sep 2023 | 71k | $218k |
| D. E. Shaw & Co | Sep 2023 | 49k | $152k |
| China Universal Asset Management | Sep 2023 | 1.1k | $3.0k |
| Deutsche Bank Aktiengesellschaft | Sep 2023 | 446.00 | $1.4k |
| Daiwa Securities Group | Sep 2023 | 104.00 | $0 |
| Simplex Trading | Dec 2023 | 67.00 | $0 |
| NISA Investment Advisors | Sep 2023 | 37.00 | $114.000700 |